I am a healthcare professional in the UK
I am a patient or member of the publicLIVTENCITY® (maribavir)
(maribavir)
(maribavir)
Welcome to the LIVTENCITY®▼ (maribavir) resource hub
LIVTENCITY®▼ (maribavir) is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).1
Consideration should be given to official guidance on the appropriate use of antiviral agents.1
Overview of LIVTENCITY
Convenient oral treatment
LIVTENCITY️ 400 mg (2 x 200 mg tablets) is taken orally twice a day.1
LIVTENCITY not require dose adjustment for renal impairment, mild or moderate hepatic impairment, or patients over 65 years.1
Double the proportion of patients achieving viremia clearance
In the pivotal Phase 3 trial, 55.7% (131/235) of transplant recipients receiving LIVTENCITY had confirmed CMV viraemia clearance† (vs 23.9% [28/117] receiving IAT*; p<0.001; primary endpoint met)1, 2
Lower incidence of neutropenia compared to Valganciclovir/ganciclovir:
1.7% (4/234) of transplant recipients
treated with LIVTENCITY experienced treatment-related neutropenia
(vs 25% [14/56] in those who received valganciclovir/ganciclovir)‡ 2, 3
Higher incidence of dysgeusia compared to the IAT arm
35.9% (84/234) of transplant recipients treated with LIVTENCITY experienced treatment-related dysgeusia (vs 0.9% [1/116] in those who received IAT) though this rarely led to treatment discontinuation (0.9% [2/234] of patients in the LIVTENCITY group)
Explore the latest resources
download
1 minute
This concise guide to LIVTENCITY® (maribavir) is designed for clarity and ease of use. It summarises key insights from the Phase 3 SOLSTICE trial, including efficacy outcomes, safety data, and practical dosing guidance.
* IAT = one or a combination of ganciclovir, valganciclovir, foscarnet, or cidofovir.
† Confirmed viraemia clearance = plasma CMV DNA < lower limit of quantification (i.e. <137 IU/mL) in 2 consecutive tests ≥5 days apart.
‡ Reported in ≥5% of patients.3
References:
- LIVTENCITY UK Summary of Product Characteristics
- Avery RK, et al. Clin Infect Dis. 2022;75(4):690–701.
- Avery RK, et al. Clin Infect Dis. 2022;75(4):690–701. Supplementary data.
Clinical Evidence
Discover key data on LIVTENCITY®▼ (maribavir) for post-transplant CMV, including the SOLSTICE study design, efficacy and safety outcomes, and insights from real-world clinical use to support healthcare professionals in evaluating treatment options.
article
4 minutes
An overview of the pivotal Phase 3 SOLSTICE trial, outlining the study design, patient population, and methodology that underpin the clinical evidence for LIVTENCITY.
video
1 minute
Insights from clinicians on the practical use of LIVTENCITY in post-transplant CMV, including case reflections and real-world treatment considerations.
article
6 minutes
A summary of the safety profile of LIVTENCITY, including adverse event data and tolerability findings from clinical studies.
article
5 minutes
Key efficacy outcomes from clinical trials evaluating LIVTENCITY in patients with post-transplant CMV, including virologic response and treatment comparisons.
Request a meeting
This is how it works:
You choose the date, time and type of contact for the scheduled meeting
Your Takeda representative confirms your appointment by email
You hold the requested meeting with your Takeda representative
Claire Pratt,
Senior Account Lead,
Transplant (North)
Jag Puaar,
Senior Account Lead,
Transplant (South)
